Abstract
The French protocol LALA 87 was designed to compare three different postinduction strategies in adult acute lymphocytic leukemia (ALL): chemotherapy, autologous transplantation, and allogeneic transplantation. This trial demonstrated a significant superiority of allogeneic bone marrow transplantation (BMT) in high-risk ALL patients. Similarly, there was a trend in favor of autologous BMT over chemotherapy in those same patients. Allogeneic BMT was not superior to autologous BMT or chemotherapy in less aggressive leukemia (standard-risk ALL). Further improvements are warranted in the treatment of adult ALL. The authors' current ongoing study is stratifying patients to allocate them to regimens with risk-adapted treatment intensity.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adolescent
-
Adult
-
Age Factors
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Belgium / epidemiology
-
Bone Marrow Transplantation*
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
France / epidemiology
-
Humans
-
Immunophenotyping
-
Life Tables
-
Middle Aged
-
Multicenter Studies as Topic
-
Philadelphia Chromosome
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
-
Prognosis
-
Remission Induction
-
Risk Factors
-
Salvage Therapy
-
Survival Analysis
-
Survival Rate
-
Transplantation, Autologous
-
Transplantation, Homologous
-
Treatment Outcome